Information  X 
Enter a valid email address

Bank of Nova Scotia (34GV)

  Print      Mail a friend

Friday 11 January, 2019

Bank of Nova Scotia

Publication of Final Terms

RNS Number : 9245M
Bank of Nova Scotia
11 January 2019
 

Publication of Final Terms

 

The following final terms dated 9 January 2019 and relating to the series CBL24 covered bonds issued on 11 January 2019 under the CAD$36 billion Global Registered Covered Bond Program of The Bank of Nova Scotia (the Final Terms) are available for viewing:

 

EUR 1,250,000,000 0.25% Covered Bonds Series CBL24 due 11 January 2024

 

The Final Terms should be read and construed in conjunction with the prospectus dated 7 February 2018, together with the First Supplementary Prospectus dated February 28, 2018, the Second Supplementary Prospectus dated April 27, 2018, the Third Supplementary Prospectus dated May 30, 2018, the Fourth Supplementary Prospectus dated July 16, 2018, the Fifth Supplementary Prospectus dated July 19, 2018, the Sixth Supplementary Prospectus dated August 29, 2018, the Seventh Supplementary Prospectus dated November 6, 2018, the Eighth Supplementary Prospectus dated November 28, 2018 and the Ninth Supplementary Prospectus dated December 19, 2018 (the Prospectus).

 

To view the Final Terms, please paste the following URL into the address bar of your browser:

 

http://www.rns-pdf.londonstockexchange.com/rns/9245M_1-2019-1-11.pdf

 

 

The Final Terms has been submitted to the National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM.

For further information, please contact:

The Bank of Nova Scotia
Scotia Plaza

44 King Street West

Toronto, Ontario

Canada M5H 1H1

 

Attn: Managing Director, Alternate Funding
Tel:      +1 416 933 7974

Fax:    +1 416 945 4001
 

Disclaimer - Intended Addressees

Please note that the information contained in this announcement and the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and Final Terms are not addressed. Prior to relying on the information contained in this announcement and the Final Terms, you must ascertain from the Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Final Terms.

In particular, this announcement and the Final Terms do not constitute an offer or invitation to subscribe for, or purchase, securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful. This announcement and the Final Terms are not for distribution in the United States or to U.S. persons (as defined below). The securities described herein have not been, and will not be, registered under the Securities Act or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. The securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America (as such terms are defined in Regulation S under the U.S. Securities Act of 1933, as amended (the Securities Act)) except pursuant to registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States. For a description of the restrictions on offers and sales of the securities described herein, please refer to the Prospectus.

Your right to access this service is conditional upon complying with the above requirement.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
PFTQFLFFKFFBBBB

a d v e r t i s e m e n t